1-Propanone, 1-(1-hexyl-6-methoxy-1H-indazol-3-yl)-2-methyl- | 691901-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-Propanone, 1-(1-hexyl-6-methoxy-1H-indazol-3-yl)-2-methyl-
• 英文别名: 1-(1-hexyl-6-methoxyindazol-3-yl)-2-methylpropan-1-one
• CAS: 691901-32-3
• 化学式: C₁₈H₂₆N₂O₂
• 分子量: 302.4
• InChiKey: OWUGFGQZCSUROJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF<br/>[FR] AGONISTE DU RECEPTEUR EP4, COMPOSITIONS ET METHODES ASSOCIEES EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2005116010A1

  公开（公告）日：2005-12-08

  This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  这项发明涉及前列腺素E2受体EP4亚型的有效选择性激动剂，其在治疗青光眼和其他与患者眼内高眼压相关的疾病中的使用或配方。此发明还涉及利用本发明化合物介导成骨细胞和破骨细胞的骨塑造和重塑过程。
• EP4 receptor agonist, compositions and methods thereof
  申请人：——

  公开号：US20040198701A1

  公开（公告）日：2004-10-07

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  这项发明涉及到前列腺素E2受体EP4亚型的强效选择性激动剂，以及它们在治疗青光眼和其他与患者眼内高眼压相关的疾病中的使用或配方。此发明还涉及将本发明的化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程。
• EP4 Receptor Agonist, Compositions and Methods Thereof
  申请人：Colucci John

  公开号：US20090270395A1

  公开（公告）日：2009-10-29

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E 2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. The compounds of the present invention are the compounds of Formula (I).

  本发明涉及到前列腺素E2受体的EP4亚型的有效选择性激动剂，以及它们在治疗青光眼和其他与患者眼内压升高有关的疾病中的使用或制剂。本发明还涉及使用本发明中的化合物来调节成骨细胞和破骨细胞的骨建模和重塑过程。本发明的化合物是式（I）的化合物。
• PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS
  申请人：Merck Frosst Canada Ltd.

  公开号：EP1613621B1

  公开（公告）日：2010-07-21
• EP1613621A1
  申请人：——

  公开号：EP1613621A1

  公开（公告）日：2006-01-11